Leading the way to a cure

Archived Scientific Meetings


The ALR's Key Industry Workshop on Lupus Clinical Trials - October 2009 in New York, NY

This past October, the ALR held an important two-day meeting in New York City:  a gathering of Pharmaceutical and biotech companies and some of the world's most informed scientists, rheumatologists, and clinical and research experts - including the ALR's Scientific Advisory Board.  The objective:  to examine the science behind lupus clinical trial from the vantage point of some of the instrumental players.

Representing the pharmaceutical and biotech companies were Amgen, Biogen Idec, Bristol-Myers Squibb, EMD Serono, Gentench and Roche, GlaxoSmithKline,  Human Genome Sciences, and UCB.  Each gave a presentation of its efforts to develop possible treatments for lupus.

This forum was an ideal setting to exchange ideas and learn about what is working and what isn’t in clinical trials.  Even though outcomes have varied — with  some trials failing and others moving forward — all are increasing our understanding of the disease and helping to direct future trials.  Many topics were covered in rigorous discussions — especially the role of B-cells and T-cells in lupus and what the scientific community continues to learn about them through targeted research.

It’s the ALR’s hope that this meeting will set the tone for even better communication between the lupus scientific community and the companies that are working to develop drugs to treat lupus.  The gathering also revealed what the ALR could do to further refine its important role in propelling critical research.

The ALR is proud to have orchestrated this significant meeting — and we thank all the participants for their willingness to share ideas — and for their ceaseless desire to help people with lupus better cope with the disease.

Maria J Leandro, MD, PhD (University College, London) and Mary Keir, PhD (Genentech)

Thomas Doerner, MD, PhD (Charite University Hospital, Berlin) and Sheila Kelly MD (LCM, Rheumatology, Bristol-Myers Squibb)

Representatives from Amgen, Biogen Idec, Bristol-Myers Squibb, EMD Serono, Gentench and Roche, GlaxoSmithKline,  Human Genome Sciences, and UCB.

Lupus Clinical Trials Meeting Steering Committee - Andrew Chan, MD, PhD (Vice President - Research Immunology,Genentech, Inc.), Betty Diamond, MD (The Feinstein Institute For Medical Research), Peter Lipsky, MD (ALR Scientific Advisory Board member), Peggy Crow, MD (Director of Rheumatology Research and Autoimmunity and Inflammation Program, Hospital for Special Surgery), Joseph Craft, MD (Yale University School of Medicine, Internal Medicine, Section of Rheumatology)

4th Annual NEIRD Conference – May 8-10 2009 in Genoa, Italy

The 4th International Conference on NeuroEndocrine Immunology in Rheumatic Diseases Translation from Basics to Clinics is taking place in Santa Margherita Ligure, Genoa, Italy from May 8th to 10th 2009. The 4th NEIRD Conference has the strong support of several International Societies for Rheumatology, including EULAR, and is likely to attract up to 250 Italian and European rheumatologists, endocrinologists, internists and immunologists. However, we expect also to attract specialists from the rest of the world. The target of the Conference will be to present interesting neuroimmunoendocrine aspects of the pathophysiology of Rheumatic Diseases presenting new aspects for diagnosis and therapeutical intervention. This edition will be particularly dedicated to the translation from Basics to Clinics with several clinical sessions on new therapies in rheumatic diseases.

For more information click here.

EULAR Meeting – June 6-10 2009 in Copenhagen, Denmark

The European League Against Rheumatism (EULAR) is the organisation which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavours to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems.

For more information click here.

13th Belgian Congress on Rheumatology - September 23-25, 2009, Mechelen, Belgium


ACR Annual Meeting – October 17-29 2009 in Philadelphia, Pennsylvania

The American College of Rheumatology is an organization of and for physicians, health professionals, and scientists that advances rheumatology through programs of education, research, advocacy and practice support that foster excellence in the care of people with arthritis and rheumatic and musculoskeletal diseases.

The ACR provides professional education for its members through several venues. The Annual Scientific Meeting, held each fall, is the premier scientific meeting devoted to the rheumatic diseases. This meeting draws thousands of rheumatologists and arthritis health professionals from around the world. A winter rheumatology symposium, spring clinical meetings, and other topical conferences round out the ACR's educational offerings.

The ACR publishes Arthritis & Rheumatism, the premier scientific journal for research in the rheumatic diseases. Arthritis Care & Research is published by the Association of Rheumatology Health Professionals, a division of the ACR. This journal focuses on the health services and clinical aspects of rheumatology.

1.5 million

people in the U.S. have Lupus.

90 million

dollars committed to lupus research by the Alliance for Lupus Research.

We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.

Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software